Kamiren Xl

Doxazosin, the active ingredient in Kamiren XL, is a alpha-1 adrenergic blocker presented as a tablet for oral use. It treats hypertension and benign prostatic hyperplasia in adult patients. GNH USA supplies Kamiren XL as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Doxazosin acts on the peripheral alpha‑1 adrenergic receptors to manage conditions related to vascular tone and smooth‑muscle contraction. - Hypertension: lowers systemic blood pressure by causing vasodilation of peripheral arteries. - Benign prostatic hyperplasia (BPH): relaxes smooth muscle in the prostate and bladder neck to improve urinary flow. - Urinary symptoms due to BPH: reduces urgency, frequency and nocturia associated with prostatic enlargement.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Peripheral edema - Nausea

Serious or Rare Side Effects: - Severe hypotension or syncope - Priapism - Allergic reactions including rash or urticaria - Angioedema - Liver function abnormalities

Before initiating therapy, consider the following safety measures. - Monitor blood pressure: check for orthostatic changes after the first dose. - Assess renal and hepatic function: dose adjustments may be needed in impairment. - Use caution in patients with a history of cardiovascular disease or arrhythmias. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Review concomitant medications that may amplify hypotensive effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Doxazosin may interact with several drug classes; clinical monitoring is advised.

Major Interactions (Avoid): - Other alpha‑1 blockers (e.g., prazosin, terazosin): additive hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increased plasma levels. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of severe hypotension. - Lithium: may raise lithium concentrations.

Moderate Interactions (Monitor Closely):\n- Diuretics: combined effect on blood pressure. - Other antihypertensives (ACE inhibitors, ARBs, beta‑blockers): additive effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy. - Antidepressants that affect norepinephrine (e.g., venlafaxine): monitor for dizziness.